NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells

Oncology Letters

Volumn 9, Issue 6, 2015, Pages 2586-2590

  Wang, Xuan ^a   Jia, Lili ^a   Jin, Xiaohua ^a   Liu, Qian ^a   Cao, Wei ^a   Gao, Xiangdong ^a   Yang, Mingfeng ^b   Sun, Baoliang ^b  

^a Sixth People's Hospital of Jinan   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; Nuclear factor B; O^{6< sup> methylguanine DNA methyltransferase}

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 [5 (4 METHYL 1 PIPERAZINYL) [2, 5' BI 1H BENZIMIDAZOL] 2' YL] PHENOL; BETA ACTIN; DIMETHYL SULFOXIDE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; SYNAPTOTAGMIN I; TEMOZOLOMIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION ASSAY; CELL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOREACTIVITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84929993979     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3130     Document Type: Article

References (20)

1. Tate MC and Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6: 447-457, 2009.
2. Grauer OM, Wesseling P and Adema GJ: Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 19: 674-693, 2009.
3. Mason WP: Emerging drugs for malignant glioma. Exprt Opin Emerg Drugs 13: 81-94, 2008.
4. Auger N, Thillet J, Wanherdrick K, et al: Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 5: 2182-2192, 2006.
5. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004.
6. Kumar A, Takada Y, Boriek AM, et al: Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) 82: 434-448, 2004.
7. Senftleben U, Cao Y, Xiao G, et al: Activation by IKKalpha of a second, evolutionary conserved, NF-kappaB signaling pathway. Science 293: 1495-1499, 2001.
8. Naugler WE and Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19-26, 2008.
9. Kapoor GS, Zhan Y, Johnson GR and O'Rourke DM: Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 24: 823-836, 2004.
10. Bredel M, Bredel C, Juric D, et al: Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24: 274-287, 2006.
11. Crinière E, Kaloshi G, Laigle-Donadey F, et al: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neuro-oncol 83: pp173-pp179, 2007.
12. Bottero V, Busuttil V, Loubat A, et al: Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61: 7785-7791, 2001.
13. Cusack JC Jr, Liu R and Baldwin AS Jr: Inducible chemoresistance to 7-ethyl-10 [4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB Activation. Cancer Res 60: 2323-2330, 2000.
14. Ma J, Murphy M, O'Dwyer PJ, et al: Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 63: 1219-1228, 2002.
15. Martinez R, Schackert G, Yaya-Tur R, et al: Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neuro-oncol 83: pp91-pp93, 2007.
16. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al: MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16: 59-65, 2008.
17. Kasuga C, Ebata T, Kayagaki N, et al: Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors. Cancer Sci 95: 840-844, 2004.
18. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, et al: The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2: 646-653, 2011.
19. Lavon I, Fuchs D, Zrihan D, et al: Novel mechanism whereby nuclear factor κB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 67: 8952-8959, 2007.
20. Huang H, Lin H, Zhang X, et al: Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Oncol Rep 27: 2050-2056, 2012.